(Q51059622)

27 March 2018

title

Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations. (English)

1 reference

27 March 2018

author

Albert de Graaf

6

1 reference

27 March 2018

Ben van Ommen

4

object named as

Ben van Ommen

0 references

author name string

Niek C A van de Pas

1

1 reference

27 March 2018

Johan A C Rullmann

2

1 reference

27 March 2018

Ruud A Woutersen

3

1 reference

27 March 2018

Ben van Ommen

4

1 reference

27 March 2018

Ivonne M C M Rietjens

5

1 reference

27 March 2018

publication date

9 August 2014

1 reference

27 March 2018

Journal of Pharmacokinetics and Pharmacodynamics

published in

1 reference

27 March 2018

volume

41

1 reference

27 March 2018

issue

4

1 reference

27 March 2018

page(s)

351-362

1 reference

27 March 2018

https://scigraph.springernature.com/pub.10.1007/s10928-014-9369-x

exact match

0 references

cites work

Plasma lipoproteins: genetic influences and clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Management of lipids in the prevention of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

New insights into the regulation of HDL metabolism and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Comparative effects of lipid-lowering therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Markers of cholesterol absorption and synthesis predict the low-density lipoprotein cholesterol response to atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Pharmacogenomics of cholesterol-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

A physiologically based in silico kinetic model predicting plasma cholesterol concentrations in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Systematic construction of a conceptual minimal model of plasma cholesterol levels based on knockout mouse phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Centering, scaling, and transformations: improving the biological information content of metabolomics data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Food-drug interaction: grapefruit juice augments drug bioavailability--mechanism, extent and relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Applicability of non-cholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

The role of serum non-cholesterol sterols as surrogate markers of absolute cholesterol synthesis and absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-014-9369-X

A physiologically-based kinetic model for the prediction of plasma cholesterol concentrations in the mouse

21 January 2018

1 reference

12 December 2020

Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin

1 reference

12 December 2020

Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system

1 reference

12 December 2020

The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine

1 reference

12 December 2020

Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types

1 reference

12 December 2020

Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population

1 reference

12 December 2020

Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity

1 reference

12 December 2020

10.1007/S10928-014-9369-X

Identifiers

DOI

1 reference

27 March 2018

PubMed ID

25106950

1 reference

27 March 2018